GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Long-Term Debt

ANL (Adlai Nortye) Long-Term Debt : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Long-Term Debt?

Adlai Nortye's Long-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.

Adlai Nortye Long-Term Debt Historical Data

The historical data trend for Adlai Nortye's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Long-Term Debt Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Long-Term Debt Get a 7-Day Free Trial - - - - -

Adlai Nortye  (NAS:ANL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Adlai Nortye Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Long-Term Debt
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.